XPO1 inhibitor combined with PD-1 in relapse/refractory primary central nervous system lymphoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300074353

Enrollment

Unknown

Registered

2023-08-04

Start date

2023-09-01

Completion date

Unknown

Last updated

2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary CNS Lymphoma

Interventions

case group:XPO1 with PD-1

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Age above 18, male or female; 2) Non Hodgkin's lymphoma was confirmed by histopathology and immunohistochemical staining, and no systemic lymphohematopoietic tissue or other systems were involved by strict physical examination and auxiliary examination, so it was definitely diagnosed as primary central nervous system lymphoma; 3) Imaging evaluation showed recurrence or progression; 4)Subjects read and fully understood the patient's instructions, and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Allergy to XPO1 inhibitors and/or PD-1 monoclonal antibodies; 2) Combined with other malignant tumors; 3) Severe heart failure, liver failure or renal failure; 4) Serious arrhythmia; 5) Female pregnancy or lactation; 6) Recent participants in other clinical trials; 7)Other serious diseases or mental disorders

Design outcomes

Primary

Measure	Time frame
progression-free survival, PFS;ORR;	—

Secondary

Measure	Time frame
Overall survival, OS;The incidence of adverse reactions;Patient tolerance;	—

Countries

China

Contacts

Public ContactYAN MA

Huashan Hospital, Fudan University

yan_ma@fudan.edu.cn+86 21 6689 5016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026